Research Overview
GHRP-6 as the founding secretagogue
GHRP-6 emerged from work by Bowers and colleagues on met-enkephalin derivatives that released growth hormone without acting through the GHRH receptor. That observation implied an unrecognised receptor, and the search for its natural ligand ended with the isolation of ghrelin from stomach tissue in 1999. GHRP-6 is therefore not merely one secretagogue among many — it is the tool compound that opened the field, and much of the receptor's early pharmacology was mapped with it.
The orexigenic signal
Central ghrelin-receptor activation drives food intake, and GHRP-6 reproduces this robustly in rodent models. Where a study's endpoint concerns appetite regulation, hypothalamic NPY/AgRP signalling or energy homeostasis, GHRP-6's lack of selectivity is the point. Investigators who need growth hormone release without that confound generally choose Ipamorelin instead.
Why it is paired with a GHRH analogue
- The two peptides act at separate receptors expressed on the same somatotroph.
- GHS-receptor agonism suppresses somatostatin tone, raising the ceiling on the GHRH response.
- Co-administration has been reported to yield a larger measured growth hormone pulse than either compound alone in animal and pituitary-cell models.
- Both are short-acting, so the combined stimulus stays pulsatile rather than continuous.